Jefferies Group’s LENZ Therapeutics LENZ Stock Holding History

Jefferies Group’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,296	Closed	-$374K	–	2012
2021 Q4	$374K	Buy	+4,296	New	+$356K	﹤0.01%	1251

Other funds holding LENZ

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Jefferies Group's LENZ Position: Q1 2022 in Review

Jefferies Group sold out of LENZ Therapeutics (LENZ) in Q1 2022, closing a stake of 4,296 shares — an estimated $374K sold.

Jefferies Group first reported a position in LENZ in Q4 2021 and held it in 1 quarter. The position peaked at $374K in Q4 2021. 63 funds tracked by Wall St. Rank hold LENZ as of Q1 2022.

Jefferies Group reported no remaining LENZ Therapeutics position as of Q1 2022 after selling out during the quarter.
Jefferies Group sold 4,296 LENZ Therapeutics shares in Q1 2022, an estimated $374K.
Jefferies Group first reported a position in LENZ Therapeutics in Q4 2021 and held it in 1 quarter.
Jefferies Group's LENZ Therapeutics position peaked at $374K in Q4 2021.
63 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2022.

Based on Jefferies Group's 13F filing for Q1 2022, filed 16 May 2022.